Suppr超能文献

玻璃体内注射贝伐单抗治疗成人期卵黄样营养不良:一例报告

Intravitreal bevacizumab for adult-onset vitelliform dystrophy: a case report.

作者信息

Montero J A, Ruiz-Moreno J M, De La Vega C

机构信息

Pio del Rio Hortega University Hospital, Ophthalmology Unit, Valladolid, Spain.

出版信息

Eur J Ophthalmol. 2007 Nov-Dec;17(6):983-6. doi: 10.1177/112067210701700620.

Abstract

PURPOSE

Adult-onset foveomacular vitelliform dystrophy (AFVD) is often misdiagnosed as occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The authors report the anatomic and functional outcome of intravitreal bevacizumab in a case of AFVD associated with a suspected occult CNV.

METHODS

Prospective, interventional, single case report. One female patient with decreased visual acuity (VA) and metamorphopsia secondary to AFVD received one single intravitreal injection of bevacizumab 1.25 mg.

RESULTS

The patient reported unchanged VA and decreased metamorphopsia 6 weeks after the injection. Fluorescein angiography (FA) and optical coherence tomography (OCT) showed progressive decrease of subretinal fluid until complete disappearance. VA, OCT, and FA remained unchanged during 10 months follow-up.

CONCLUSIONS

Intravitreal bevacizumab showed a morphologic improvement and stable VA in a patient with AFVD. Further case series are required to confirm this observation.

摘要

目的

成人迟发性黄斑部卵黄样营养不良(AFVD)常被误诊为年龄相关性黄斑变性(AMD)继发的隐匿性脉络膜新生血管(CNV)。作者报告了1例合并疑似隐匿性CNV的AFVD患者玻璃体内注射贝伐单抗后的解剖学和功能结果。

方法

前瞻性、干预性单病例报告。1例因AFVD导致视力下降(VA)和视物变形的女性患者接受了1次1.25mg玻璃体内贝伐单抗注射。

结果

患者在注射后6周报告视力无变化,但视物变形减轻。荧光素血管造影(FA)和光学相干断层扫描(OCT)显示视网膜下液逐渐减少直至完全消失。在10个月的随访期间,视力、OCT和FA均保持不变。

结论

玻璃体内注射贝伐单抗在1例AFVD患者中显示出形态学改善且视力稳定。需要进一步的病例系列研究来证实这一观察结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验